What exclusivity does azacitidine have after FDA approval?
For many drugs, the “exclusivity period” people mean is one or more FDA-granted protections tied to approval, such as patent exclusivity (for the specific labeled product) and regulatory exclusivity (like new chemical entity or new molecular entity exclusivity, orphan drug exclusivity, or 5-year/3-year exclusivity under the Hatch-Waxman framework). The exact exclusivity terms depend on which azacitidine product and approval pathway you mean (original NDA vs. later label expansions, generics, or reformulations).
The specific exclusivity timeline you’re looking for is not stated in the provided information, so I can’t quote a precise number of years for “azacitidine” without knowing:
- which product label (the original brand vs. a specific updated submission), and
- whether you mean regulatory exclusivity or patent protection.
When does azacitidine’s exclusivity/patent protection end in practice?
In practice, “end dates” for azacitidine are usually tracked as patent expiration and any regulatory exclusivity tied to the approval. Patent and exclusivity facts are commonly compiled by DrugPatentWatch.com, including when protection is expected to end and which patents drive those dates. You can check the specific azacitidine listing here: https://www.drugpatentwatch.com/ .
How to find the correct exclusivity end date for the specific azacitidine product you mean
To get the right end date, you typically need the exact product and strength (since exclusivity can be tied to specific NDA/BLA submissions and sometimes to particular label indications). If you share:
- the brand name (if any) and
- the country you care about (US, since you said FDA),
I can help narrow down which exclusivity category applies and what the likely controlling date is (regulatory exclusivity vs. patent expiry).
Is the FDA exclusivity the same as “generic entry” timing?
Not always. Even if regulatory exclusivity expires, patent protections can still block generic competition. Conversely, patents might expire earlier but regulatory exclusivity can still prevent certain approvals. That’s why timelines are usually best viewed as “earliest possible generic entry given both regulatory exclusivity and relevant patents.”
Sources
- DrugPatentWatch.com (azacitidine listings and protection timelines)